<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941886</url>
  </required_header>
  <id_info>
    <org_study_id>2018-0434</org_study_id>
    <nct_id>NCT03941886</nct_id>
  </id_info>
  <brief_title>Implementation of First-trimester Screening and preventiOn of pREeClAmpSia Trial (FORECAST)</brief_title>
  <acronym>FORECAST</acronym>
  <official_title>Implementation of First-trimester Screening and Prevention of Preeclampsia: a Stepped Wedge Cluster-randomized Trial in Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiu Yee Liona Poon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This implementation study aims to evaluate the efficacy, acceptability, and safety of
      first-trimester screening and prevention for preterm-preeclampsia. It is a multicenter
      stepped wedge cluster randomized trial including maternity / diagnostic units from ten
      regions in Asia. The study involves a period where no intervention will take place at all
      recruiting units, and then at regular intervals, one cluster will be randomized to transit
      from non-intervention group to intervention group in which first-trimester screening for
      preterm-preeclampsia by the Bayes based method followed by the commencement of low-dose
      aspirin in high-risk women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a stepped wedge cluster-randomized trial. There are total of 7 clusters across Asia. This study involves a period where no intervention will take place at all recruiting units, i.e. routine prenatal care, and then at regular intervals (every 6 weekly), one cluster will be randomized to transit from non-intervention group to intervention group in which first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis for high-risk women.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delivery with preterm-preeclampsia</measure>
    <time_frame>Before 37 weeks of gestation</time_frame>
    <description>Proportions of delivery with preterm-preeclampsia between non-intervention and intervention groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse outcomes with delivery at &lt;34, &lt;37 and ≥37 weeks of gestation</measure>
    <time_frame>at &lt;34, &lt;37 and ≥37 weeks of gestation</time_frame>
    <description>including preeclampsia, gestational hypertension, small for gestational age birth weight (&lt;5th percentile), stillbirth, placental abruption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal mortality</measure>
    <time_frame>during the first 28 days of life (0-27 days)</time_frame>
    <description>A neonatal death is a death during 0-27 days of life. Composite neonatal morbidity (any one of the following): &gt; grade II intraventricular hemorrhage; neonatal sepsis confirmed by cultures; neonatal anemia requiring transfusion; respiratory distress syndrome requiring surfactant and ventilation; necrotising enterocolitis requiring surgical intervention.
Composite neonatal therapy (any one of the following): Neonatal high dependency or intensive care unit admission; Ventilation - need of positive pressure or intubation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low birth weight</measure>
    <time_frame>at birth</time_frame>
    <description>Low birth weight &lt;3rd, 5th and 10th percentile</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>at or after 20 to 28 weeks of pregnancy</time_frame>
    <description>Fetal death at or after 20 to 28 weeks of pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous preterm birth</measure>
    <time_frame>At &lt;34 and &lt;37 weeks' gestation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The willingness of subjects accept to receive preeclampsia screening under the Bayes based method</measure>
    <time_frame>in the first trimester of pregnancy (11-13 weeks of gestation)</time_frame>
    <description>If subjects are under the intervention group upon proper consent procedure is done, at 11-13 weeks of gestation, the procedures below will be done.
Collection of maternal information (obstetrical, medical and drug history including aspirin intake with indication)
Measurement of maternal MAP and UtA-PI will be measured according to standardized protocols.
Blood sample will be drawn to determine of serum level of PIGF.
The individual study participant's risk of preterm-PE will be computed using the Bayes based method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The willingness of high-risk subjects to accept aspirin treatment</measure>
    <time_frame>from &lt;15 weeks till 36 weeks of gestation or, in the event of early delivery, at the onset of labor</time_frame>
    <description>When patients are subjected to be high risks in preeclampsia screening, they will be asked if they accept the aspirin for treatment. If they do not accept, they will continue with routine care. The willingness of subjects will all be recorded on the Case report forms for data collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal morbidity</measure>
    <time_frame>during the first 28 days of life (0-27 days)</time_frame>
    <description>Composite neonatal morbidity (any one of the following): &gt; grade II intraventricular hemorrhage; neonatal sepsis confirmed by cultures; neonatal anemia requiring transfusion; respiratory distress syndrome requiring surfactant and ventilation; necrotising enterocolitis requiring surgical intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite neonatal therapy</measure>
    <time_frame>during the first 28 days of life (0-27 days)</time_frame>
    <description>Neonatal high dependency or intensive care unit admission; Ventilation - need of positive pressure or intubation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52920</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>Non-intervention group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants receive routine prenatal care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive first-trimester screening for preterm-preeclampsia by the Bayes based method followed by commencement of low-dose aspirin prophylaxis in high-risk women.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-dose aspirin in women with high risk of preeclampsia</intervention_name>
    <description>Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight &lt;40 Kg, from &lt;15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy;

          -  Live fetus;

        Exclusion Criteria:

          -  Multiple pregnancy;

          -  Major fetal defects identified at 11-13 weeks of assessment;

          -  Non-viable fetus (missed spontaneous abortion or stillbirth).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liona CY Poon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liona CY Prof Poon, MD</last_name>
    <phone>(852) 3505 2582</phone>
    <email>liona.poon@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kunming Angel Women &amp; Children Hospital</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruimei Ma, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yali Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kwong Wah Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wing Cheong Leung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harapan Kita Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aditya Kusuma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Fetal Medicine</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritsuko K Pooh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akihiko Sekizawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Japan Society for the Study of Hypertension in Pregnancy</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shigeru Saito</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusat Perubatan Universiti Kebangsaan Malaysia (UKM) Medical Centre</name>
      <address>
        <city>Bandar Tun Razak</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaleha Abdullah Mahdy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Aguilar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahesh A Choolani, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Shaw, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taiji Clinic</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tung-Yao Chang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noppadol Chaiyasit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuangsit Wataganara, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suchaya Luewan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Khlong Luang</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tongta Nanthakomon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanoi Obstetrics &amp; Gynecology Hospital</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linh Dinh, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Indonesia</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <reference>
    <citation>Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol. 1988 Jan;158(1):80-3.</citation>
    <PMID>2962500</PMID>
  </reference>
  <reference>
    <citation>Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010 Aug 21;376(9741):631-44. doi: 10.1016/S0140-6736(10)60279-6. Epub 2010 Jul 2. Review.</citation>
    <PMID>20598363</PMID>
  </reference>
  <reference>
    <citation>Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006 Apr 1;367(9516):1066-1074. doi: 10.1016/S0140-6736(06)68397-9. Review.</citation>
    <PMID>16581405</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-31. doi: 10.1097/01.AOG.0000437382.03963.88.</citation>
    <PMID>24150027</PMID>
  </reference>
  <reference>
    <citation>Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, Zeeman GG, Brown MA. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014 Apr;4(2):97-104. doi: 10.1016/j.preghy.2014.02.001. Epub 2014 Feb 15.</citation>
    <PMID>26104417</PMID>
  </reference>
  <reference>
    <citation>National Collaborating Centre for Women's and Children's Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London: RCOG Press; 2010 Aug.</citation>
    <PMID>22220321</PMID>
  </reference>
  <reference>
    <citation>Committee Opinion No. 638: First-Trimester Risk Assessment for Early-Onset Preeclampsia. Obstet Gynecol. 2015 Sep;126(3):e25-7. doi: 10.1097/AOG.0000000000001049. Review.</citation>
    <PMID>26287789</PMID>
  </reference>
  <reference>
    <citation>Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol. 2015 Jul;213(1):62.e1-62.e10. doi: 10.1016/j.ajog.2015.02.018. Epub 2015 Feb 25.</citation>
    <PMID>25724400</PMID>
  </reference>
  <reference>
    <citation>O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation. Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12. doi: 10.1016/j.ajog.2015.08.034. Epub 2015 Aug 19.</citation>
    <PMID>26297382</PMID>
  </reference>
  <reference>
    <citation>O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, Carbone IF, Dutemeyer V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos A, Plasencia W, Nicolaides KH. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017 Jun;49(6):756-760. doi: 10.1002/uog.17455. Erratum in: Ultrasound Obstet Gynecol. 2017 Dec;50(6):807.</citation>
    <PMID>28295782</PMID>
  </reference>
  <reference>
    <citation>Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017 Aug 17;377(7):613-622. doi: 10.1056/NEJMoa1704559. Epub 2017 Jun 28.</citation>
    <PMID>28657417</PMID>
  </reference>
  <reference>
    <citation>Plasencia W, Maiz N, Poon L, Yu C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks and 21 + 0 to 24 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008 Aug;32(2):138-46. doi: 10.1002/uog.5402.</citation>
    <PMID>18634131</PMID>
  </reference>
  <reference>
    <citation>Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation. Fetal Diagn Ther. 2012;31(1):42-8. doi: 10.1159/000335366. Epub 2012 Jan 13.</citation>
    <PMID>22248988</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>December 31, 2019</last_update_submitted>
  <last_update_submitted_qc>December 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Chiu Yee Liona Poon</investigator_full_name>
    <investigator_title>Professor (Clinical)</investigator_title>
  </responsible_party>
  <keyword>Pre-Eclampsia</keyword>
  <keyword>Aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

